Pharmaceutical formulation for nasal administration
US6623732B1 · kind B1 · utility
Assignees
Inventor
Key dates
| Filing date | Jan 8, 2001 |
| Grant date | Sep 23, 2003 |
| Priority date | — |
| Expiry date | Jan 8, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/728
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention discloses a pharmaceutical formulation for nasal administration which contains a pharmaceutically active polypeptide and a method producing the pharmaceutical formulation. The pharmaceutical for formulation comprises: (1) a pharmaceutically active polypeptide, (2) at least one compound selected from the group consisting of taurine, an ester thereof with C1˜6 alcohol, a base metal salt of taurine, hyaluronic acid and a base metal of hyaluronic acid and (3) at least one pharmacologically acceptable additive. It exhibited excellent pharmaceutical activity. No adverse effects such as irration were observed and hence, the present pharmaceutical formulation may suitably be administered nasal mucosa.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.